NBEAL2 deficiency in humans leads to low CTLA-4 expression in activated conventional T cells

Laure Delage,Francesco Carbone,Quentin Riller,Jean-Luc Zachayus,Erwan Kerbellec,Armelle Buzy,Marie-Claude Stolzenberg,Marine Luka,Camille de Cevins,Georges Kalouche,Rémi Favier,Alizée Michel,Sonia Meynier,Aurélien Corneau,Caroline Evrard,Nathalie Neveux,Sébastien Roudières,Brieuc P Pérot,Mathieu Fusaro,Christelle Lenoir,Olivier Pellé,Mélanie Parisot,Marc Bras,Sébastien Héritier,Guy Leverger,Anne-Sophie Korganow,Capucine Picard,Sylvain Latour,Bénédicte Collet,Alain Fischer,Bénédicte Neven,Aude Magérus,Mickaël Ménager,Benoit Pasquier,Frédéric Rieux-Laucat
DOI: https://doi.org/10.1038/s41467-023-39295-7
2023-06-22
Abstract:Loss of NBEAL2 function leads to grey platelet syndrome (GPS), a bleeding disorder characterized by macro-thrombocytopenia and α-granule-deficient platelets. A proportion of patients with GPS develop autoimmunity through an unknown mechanism, which might be related to the proteins NBEAL2 interacts with, specifically in immune cells. Here we show a comprehensive interactome of NBEAL2 in primary T cells, based on mass spectrometry identification of altogether 74 protein association partners. These include LRBA, a member of the same BEACH domain family as NBEAL2, recessive mutations of which cause autoimmunity and lymphocytic infiltration through defective CTLA-4 trafficking. Investigating the potential association between NBEAL2 and CTLA-4 signalling suggested by the mass spectrometry results, we confirm by co-immunoprecipitation that CTLA-4 and NBEAL2 interact with each other. Interestingly, NBEAL2 deficiency leads to low CTLA-4 expression in patient-derived effector T cells, while their regulatory T cells appear unaffected. Knocking-down NBEAL2 in healthy primary T cells recapitulates the low CTLA-4 expression observed in the T cells of GPS patients. Our results thus show that NBEAL2 is involved in the regulation of CTLA-4 expression in conventional T cells and provide a rationale for considering CTLA-4-immunoglobulin therapy in patients with GPS and autoimmune disease.
What problem does this paper attempt to address?